Deep sequencing of the Moderna and Pfizer bivalent vaccines identifies contamination of expression vectors designed for plasmid amplification in bacteria | Kevin McKernan

1 March 2023 | As universities in the United States continue to mandate liability-free injections (COVID vaccines) for students at limited risk of contracting COVID, it becomes imperative that more public information be made available for the ingredients of these experimental vaccines. Both the EMA and the TGA have made note of fragmented RNA and smeary western blots suggesting the vaccine manufacturing process lacks fidelity and transparency. Shortly after the TGA data was released, Patel et al. (Pfizer) published a paper attempting to defuse these concerns.

This technical presentation and article at investigate this finding.

Kevin McKernan is the CSO and Founder of Medicinal Genomics and has pioneered the genomics of cannabis and hemp to build a stronger scientific environment ( for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics.

Previously, Kevin was the CSO of Courtagen Life Sciences, Inc., and was Vice President and Director of R&D of Life Technologies where he managed the development of Life Technologies next generation SOLiD sequencing technology. Integral to the SOLiD R&D process, Kevin oversaw over 100 research collaborations exploring the new biological frontiers with next generation sequencing and saw particular excitement and traction in human tumor sequencing. Kevin initiated an R&D project to investigate chemFET semiconductor based DNA sequencing and spearheaded a process to acquire the DNA sequencing company Ion Torrent for $350M. These collaborations resulted in hundreds of publications and 7 Journal covers from Science Translational Medicine to Nature.

Kevin was the President and CSO of Agencourt Personal Genomics, a startup company he co-founded in 2005 to invent revolutionary sequencing technologies that dropped the cost of sequencing a human genome from $300M to $3,000; a 100,000-fold improvement in sequencing speed and cost in a few years. In 2000, Kevin Co-Founded Agencourt Biosciences Corporation and acted as the CSO until it was acquired by Beckman Coulter. Kevin also managed the R&D for the Human Genome Project at Whitehead Institute/MIT resulting in several patents for nucleic acid purification. Kevin holds a B.S. in Biology from Emory University with a focus on cloning and expressing Norepinephrine Transporters. When not decoding DNA and unraveling the mysteries of cannabis medicine, Kevin enjoy boating, skiing, and gardening.

PANDA’s weekly Open Science Sessions provide an opportunity for science, research and policy to be presented by various leading international experts in a variety of diverse fields. These sessions aim to broaden understanding and inspire new insights.

See more of our Open Science Sessions here:
Support our work:

Loading 3 comments...